NCT02513095View on ClinicalTrials.gov

Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

October 31, 2015

Conditions
Heat Stroke
Interventions
DRUG

Dantrolene sodium for injectable suspension

Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.

Trial Locations (1)

Unknown

Mecca

Sponsors
All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

Eagle Pharmaceuticals, Inc.

INDUSTRY

NCT02513095 - Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS) | Biotech Hunter | Biotech Hunter